PODXL and esophageal adenocarcinoma: The present study demonstrates a superior prognosis for patients with gastric or esophageal adenocarcinoma with high PODXL expression, treated with neoadjuvant ± adjuvant fluoropyrimidine- and oxaliplatin-based chemotherapy, compared to those with negative or low PODXL expression.